Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29752538 | 1.00 | KDM4E (0.60) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL123685 | 1.00 | KDM4E (0.60) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL3685090 | 1.00 | KDM4E (0.60) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL26661419 | 1.00 | KDM4E (0.60) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL6330240 | 0.95 | KDM4E (0.54) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| Formaldehyde SCHEMBL21638814 | 0.94 | KDM4E (0.54) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| Meglumine SCHEMBL29757165 | 0.92 | KDM4E (0.76) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL9444652 | 0.85 | LMNA (0.65) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL29344590 | 0.85 | LMNA (0.65) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL5551085 | 0.85 | LMNA (0.65) | KDM4ELMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846939-B2 | Salts and mixture of 9-oxoacridine-10-acetic acid with 1-alkylamino-1-desoxy-polyols, pharmaceutical compositions containing said agents and treatment methods | EPHAG AS (EE) | 2010-12-07 | — | — | US | disclosed |
| EP-1970372-B1 | SALTS OF 9-OXOACRIDINE-10-ACETIC ACID WITH 1-ALKYLAMNO-1-DESOXY-POLYOLS | EPHAG AS (EE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100144780-A1 | Salts and Mixture of 9-Oxoacridine-10-Acetic Acid with 1-Alkylamino-1-Desoxy-Polyols, Pharmaceutical Compositions Containing Said Agents and Treatment Methods | PJSC PHARMSYNTHEZ (RU) | 2010-06-10 | — | — | US | disclosed |
| EP-1970372-A2 | SALTS OF 9-OXOACRIDINE-10-ACETIC ACID WITH 1-ALKYLAMNO-1-DESOXY-POLYOLS | EPhaG AS (EE) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144780-A1 | Salts and Mixture of 9-Oxoacridine-10-Acetic Acid with 1-Alkylamino-1-Desoxy-Polyols, Pharmaceutical Compositions Containing Said Agents and Treatment Methods | ADSL, ACMSD, ASS1 | KDM4E 3727/4885LMNA 621/4885L3MBTL1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.